Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report

被引：16
|
作者：
Qiao, Yu [1 ,2 ]
Yang, Jihong [1 ,3 ]
Liu, Lili [1 ,3 ]
Zeng, Yixin [1 ,2 ]
Ma, Jie [4 ]
Jia, Jing [1 ]
Zhang, Li [5 ]
Li, Xiaoguang [6 ]
Wu, Peihong [7 ]
Wang, Wenchao [8 ]
Liu, Dongge [9 ]
Chen, Huan [1 ,3 ]
Zhao, Yunbo [1 ,2 ]
Xi, Huan [1 ]
Wang, Yao [1 ]
机构：
[1] Beijing Hosp, Natl Ctr Gerontol, Dept Geriatr, Beijing 100730, Peoples R China
[2] Beijing Hosp, Natl Ctr Gerontol, Dept Oncol, Beijing 100730, Peoples R China
[3] Beijing Hosp, Natl Ctr Gerontol, Dept Nephrol, Beijing 100730, Peoples R China
[4] Beijing Hosp, Natl Ctr Gerontol, Biol Treatment Ctr, Beijing 100730, Peoples R China
[5] Zhongshan Univ, Tumor Hosp, Dept Oncol, Guangzhou 510089, Guangdong, Peoples R China
[6] Beijing Hosp, Natl Ctr Gerontol, Minimally Invas Tumor Therapies Ctr, Beijing 100730, Peoples R China
[7] Zhongshan Univ, Tumor Hosp, Ctr Med Image Guided Minimally Invas Therapy, Guangzhou 510089, Guangdong, Peoples R China
[8] Beijing Hosp, Natl Ctr Gerontol, Dept Imaging, Beijing 100730, Peoples R China
[9] Beijing Hosp, Natl Ctr Gerontol, Dept Pathol, Beijing 100730, Peoples R China
来源：
BMC CANCER | 2018年 / 18卷
关键词：
Primary hepatic angiosarcoma; Pazopanib; PD-1; inhibitor; RAK cell; IMMUNOTHERAPY; CARCINOMA; ABLATION; FEATURES; OUTCOMES; LIVER;
D O I：
10.1186/s12885-018-3996-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: Primary hepatic angiosarcoma (PHA) is a rare and aggressive solid tumor, with high rates of local recurrence and distant metastasis, and poor prognosis. There are no established treatment guidelines for PHA. Case presentation: A 78-year-old asymptomatic man with PHA that was successfully treated with pazopanib plus PD-1 inhibitor and RetroNectin-activated killer cells (RAK cells). After one month of treatment, there was a clear reduction in the size and number of the liver metastases; and after nearly 15 months, most of the lesions were stable, no new lesions had developed, and the side effect of treatment was minor. Conclusion: Pazopanib, PD-1 inhibitor and RAK cells could serve as a potential option for the treatment of advanced PHA.
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Efficacy and safety of PD-1 inhibitor combined with anlotinib in the treatment of advanced
    Song, L.
    Yu, X.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 145 - 145
  • [22] TACE plus PD-1 inhibitor (Camrelizumab) treatment for bridging to tumor resection in HCC: Case reports
    Xin, Haibei
    Zhang, Cunzhen
    Ding, Zhiwen
    Zhang, Minfeng
    Ding, Guanghui
    Li, Nan
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2022, 46 (01)
  • [23] Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma
    Huang, YeXing
    Du, ZeFeng
    Kan, Anna
    He, MinKe
    Li, HuiFang
    Lai, ZhiCheng
    Wen, DongSheng
    Huang, LiChang
    Li, QiJiong
    Xu, Li
    Shi, Ming
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [24] PD-1 Inhibitor Induced Hypertrophic Lichen Planus: A Case Report
    Lim, Olivia
    Maher, Eamonn
    Miller, Daniel D.
    DRUGS IN R&D, 2024, 24 (02) : 353 - 357
  • [25] Acquired Perforating Dermatosis Induced by PD-1 Inhibitor: A Case Report
    Liu, Xiaoyan
    Wang, Huayang
    Wan, Yinsheng
    Guo, Ying
    Shan, Shi-Jun
    AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2021, 43 (12) : 942 - 944
  • [26] PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature
    Wang, Zhihong
    Zeng, Tianmei
    Li, Yong
    Zhang, Ding
    Yuan, Zhengang
    Huang, Mengli
    Yang, Yuan
    Zhou, Weiping
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [27] Survivals following discontinuation of PD-1 inhibitor treatment in advanced melanoma patients
    Kartolo, Adi
    Tong, Justin
    Yeung, Cynthia
    Kuksis, Markus
    Hopman, Wilma
    Baetz, Tara
    MELANOMA RESEARCH, 2023, 33 (01) : 50 - 57
  • [28] PD-1 inhibitor treatment in a penile cancer patient with MMR/MSI status heterogeneity: A case report
    Du, YunYi
    Zhang, XiaoLing
    Zhang, Ying
    Li, WeiLing
    Hu, WenQing
    Zong, Liang
    Zhao, Jun
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (06)
  • [29] Treatment of PD-1 Inhibitor-Associated Toxic Epidermal Necrolysis: A Case Report and Brief Review
    Zhao, Yidong
    Cao, Yuzhen
    Wang, Xiuyu
    Qian, Tianyi
    ONCOTARGETS AND THERAPY, 2022, 15 : 345 - 351
  • [30] Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review
    De Bock, Marlies
    Hulstaert, Eva
    Kruse, Vibeke
    Brochez, Lieve
    CASE REPORTS IN DERMATOLOGY, 2018, 10 (02): : 190 - 197
12345